Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Meiji Seika’s Korean JV Passes GMP Inspection by PMDA, Preparing for Contract Production of Nesp Biosimilar
September 27, 2019
- Otsuka Files for Abilify Once-Monthly Injection for Bipolar Disorder in Japan
September 27, 2019
- Takeda’s Sakigake-Designated Narcolepsy Drug Prolongs Sleep Latency in PI
September 27, 2019
- Entyvio Shows Superiority to Humira in Clinical Remission in Comparison Study: Takeda
September 27, 2019
- Amid Slow Uptake, Sysmex Pitching Its Genomic Profiling via Close Communications with Hospitals, Govt: Exec
September 27, 2019
- Takeda’s TAK-620 Shows Antiviral Activities for CMV Infection in PII
September 26, 2019
- Biogen Japan Chairman Torii to Resign Sept. 30
September 26, 2019
- Chugai’s Comprehensive Genomic Profiling Test Approved for Companion Diagnostic for Lynparza
September 26, 2019
- Mylan EPD Submits Clinical Trial Application in Japan for PIII Study of Eyedrop Therapy for Cystinosis
September 26, 2019
- Chinese Regulators Accept Tenelia for Review
September 25, 2019
- Astellas’ AML Drug Gets European Panel Backing
September 25, 2019
- Mylan to Distribute Eisai’s Cancer Treatment Halaven under Brand Name of Teceris in India
September 24, 2019
- Kyoto Univ. Spinout Boots Up to Develop iPSC-Based Kidney Therapy
September 24, 2019
- Mitsubishi Tanabe to Join Promotion for Santen’s Alesion Eye Drops
September 24, 2019
- Kissei Kicks Off Japan PIII for ITP Drug Fostamatinib
September 24, 2019
- SanBio’s Lead Cell Therapy Rides High with FDA’s RMAT Designation for Traumatic Brain Injury
September 20, 2019
- JCR Drops Temcell Submission for Epidermolysis Bullosa
September 20, 2019
- Kyowa Kirin to Keep Challenging to Boost Global Footprint: President
September 20, 2019
- Japan’s 1st Forteo Biosimilar Nears Market, Mochida Looks at Billion-Yen Sales
September 19, 2019
- US FDA Gives 1st Nod for Lenvima/Keytruda Combo as 2nd-Line Therapy for Endometrial Carcinoma
September 19, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…